Advertisement

Topics

Novartis Edges Closer to Getting Neurological Gene Therapy to Clinic

14:06 EDT 8 May 2019 | Labiotech.eu

Novartisgene therapy for the rare disease spinal muscular atrophy is long-lasting as well as effective, suggests evidence that brings it even closer to the clinic. Novartis trialed its gene therapy Zolgensma in 10 patients under six months of age, who had the genetic condition spinal muscular atrophy (SMA). In SMA type 1, the most […]

The post Novartis Edges Closer to Getting Neurological Gene Therapy to Clinic appeared first on Labiotech.eu.

Original Article: Novartis Edges Closer to Getting Neurological Gene Therapy to Clinic

NEXT ARTICLE

More From BioPortfolio on "Novartis Edges Closer to Getting Neurological Gene Therapy to Clinic"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...